ashleyk
10-10-2006, 09:31 AM
Hi, great to see this site back! Found this news release on yahoo last week. The MJF foundation is looking for new drug therapies for PD and intends to fund up to $2 million for the research.
http://news.yahoo.com/s/usnw/20061004/pl_usnw/michael_j__fox_foundation_seeks_novel_drug_develop ment_strategies_for2007_target_validation_initiati ve140_xml
So I emailed the MJF with my suggestion to look at Low Dose Naltrexone. I have to say I received a rather vague reply and I wonder what they are thinking. LDN is safe, cheap and available now but there have been no clinical trials on it.
Ashley
From a NIH report on naloxone/naltrexone.
Current replacement therapy with L-dopa is able to alleviate disease symptoms, but is unable to alter the disease course. Thus, therapeutic interventions designed to inhibit the microglial inflammatory response offer hope for attenuation of the neurodegenerative disease process. The current anti-inflammatory treatments available, including steroids and nonsteroidal anti-inflammatory drugs, are limited by the ability to influence only a small portion of the microglial response (10) . Thus, identification of compounds acting on novel targets to inhibit the release of a wide range of proinflammatory factors from overactivated microglia is of paramount importance. In the ensuing study, we report that femtomolar concentrations of naloxone and the peptide fragment glycine-glycine-phenylalanine (GGF) attenuate a broad spectrum of the microglia inflammatory response (reactive oxygen species (ROS) and proinflammatory factors) and are neuroprotective with extremely potent efficacy through the inhibition of microglial NADPH oxidase.
http://www.lowdosenaltrexone.org/index.htm
http://news.yahoo.com/s/usnw/20061004/pl_usnw/michael_j__fox_foundation_seeks_novel_drug_develop ment_strategies_for2007_target_validation_initiati ve140_xml
So I emailed the MJF with my suggestion to look at Low Dose Naltrexone. I have to say I received a rather vague reply and I wonder what they are thinking. LDN is safe, cheap and available now but there have been no clinical trials on it.
Ashley
From a NIH report on naloxone/naltrexone.
Current replacement therapy with L-dopa is able to alleviate disease symptoms, but is unable to alter the disease course. Thus, therapeutic interventions designed to inhibit the microglial inflammatory response offer hope for attenuation of the neurodegenerative disease process. The current anti-inflammatory treatments available, including steroids and nonsteroidal anti-inflammatory drugs, are limited by the ability to influence only a small portion of the microglial response (10) . Thus, identification of compounds acting on novel targets to inhibit the release of a wide range of proinflammatory factors from overactivated microglia is of paramount importance. In the ensuing study, we report that femtomolar concentrations of naloxone and the peptide fragment glycine-glycine-phenylalanine (GGF) attenuate a broad spectrum of the microglia inflammatory response (reactive oxygen species (ROS) and proinflammatory factors) and are neuroprotective with extremely potent efficacy through the inhibition of microglial NADPH oxidase.
http://www.lowdosenaltrexone.org/index.htm